|
3-hrs Webinar-Deciding When to Submit a 510(k)
Everyday
10.00 AM
http://https://worldcomplianceseminars.com/webinardetails/319
Hollywood
FL Wisconsin 33021
Report Abuse
|
|
3-hrs Webinar-Deciding When to Submit a 510(k) for a Change to an Existing Device – FDA’s Final Guidance
Description
A premarket notification (510(k)) is required when a legally marketed device subject to 510(k) requirements is about to be significantly changed or modified in design, components, method of manufacture, or intended use. Significant changes or modifications are those that could significantly affect the safety or effectiveness of the device, or major changes or modifications in the intended use of the device (21 CFR 807.81(a)(3)).
This presentation, will aid manufacturers of medical devices who intend to modify a 510(k)-cleared device or a preamendments device subject to 510(k) (i.e., “existing devices”) during the process of deciding whether the modification exceeds the regulatory threshold of 21 CFR 807.81(a)(3) for submission and clearance of a new 510(k).
Why should you attend
This presentation uses the latest FDA thinking and guidance documents to assist the manufacturers in enhancing the predictability, consistency, and transparency of the “when to submit” decision-making process by providing a least burdensome approach, and describing in greater detail the regulatory framework, policies, and practices underlying such a decision.
Case Study Examples will be provided for each session to further assist the attendees in understanding how to decide when to submit a 510(k) for a change to an existing device.
Areas Covered
Session #: 1
Duration: 30 minutes
Learning Objectives: The main types of changes that might be made to a device: When a manufacturer modifies their device with the intent to significantly affect the safety and effectiveness of a device (for example to significantly improve clinical outcome or to mitigate a known risk) submission of a new 510(k) is likely. Other changes, however, need to be evaluated for whether the change could significantly affect device safety and effectiveness plus for whether the change impacts the device substantial equivalence from the existing device.
1. Changes made with intent to affect device safety & effectiveness
2. Initial Risk Based Assessment
3. Use of Risk Management
4. The role of validation & verification to determine whether a change could significantly affect device safety and effectiveness
5. Evaluating simultaneous changes to determine whether submission of a new 510(k) is required
6. Appropriate comparative device and cumulative effect of changes
7. Substantial equivalence determination
Session #: 2
Duration: 30 minutes
Learning Objectives: Labeling changes: This session identifies several types of labeling changes or modifications to an existing device, including certain changes to the indications for use, that can have a major impact on intended use and thus require submission of a new 510(k). Focusing on indications for use and using a risk-based assessment for labeling changes to help identify those changes that are more frequently recommended for documentation only, are discussed.
1. Is it a change in the indications for use statement?
2. Does the change add or delete a contra-indication?
3. Is it a change in warnings or precautions?
4. Could the change affect the directions for use of the device?
BREAK –
Session #: 3
Duration: 30 minutes
Learning Objectives: Technology, engineering, and performance changes: These types of changes encompass a broad span of design activities, from minor engineering changes in a circuit board layout to a change from electromechanical to microprocessor control of device function. They need to be evaluated and verified and/or validated according to the QS requirements. If the results of the verification and/or validation raise any unexpected issues, how to determine whether submission of a new 510(k) is required.
1. Is the device an in vitro diagnostic device?
2. Is it a control mechanism, operating principle, or energy type change?
3. Is it a change in sterilization, cleaning, or disinfection?
4. Is it a change to an “established category B” or “novel” sterilization method, does the change lower the sterility assurance level, or is it a change to how the device is provided?
5. Could the change significantly affect the performance or biocompatibility of the device?
6. Is there a change in packaging or expiration dating?
7. Is the same method or protocol, as described in a previously cleared 510(k), used to support the change?
8. Is it any other change in design (e.g., dimensions, performance specifications, wireless communication, components or accessories, or the patient/user interface)?
Session #: 4
Duration: 30 minutes
Learning Objectives: Materials changes: Firms making changes to the materials from which their device is manufactured need to consider the changes discussed above and their impact on the decision regarding submission of a new 510(k). For example, a material change, might also lead to a change in the labeling of the device (e.g., the removal of a contraindication or the addition of a new warning), or a change in specifications (e.g., a reduction in the strength of the device).
1. Is the device an in vitro diagnostic device?
2. Is this a change in material type, material formulation, chemical composition, or the material’s processing?
3. Will the changed material directly or indirectly contact body tissues or fluids?
4. Does a risk assessment identify any new or increased biocompatibility concerns?
5. Has the manufacturer used the same material in a similar legally marketed device?
6. Could the change affect the device’s performance specifications?
BREAK –
Session #: 5
Duration: 30 minutes
Learning Objectives: Technology, engineering, performance, and materials changes for in vitro diagnostic devices (IVDs): Changes in technology, engineering, performance, or materials of an IVD can include changes made to reagents or changes to a test method or protocol, among other things. This session will examine whether these changes require a 510(k) to be submitted, as well as whether other changes, e.g. labeling changes need to be made.
1. Does the change alter the operating principle of the IVD?
2. Is the change identified in a device-specific final guidance or classification regulation?
3. Does a risk-based assessment of the changed device identify any new risks or significantly modified existing risks?
4. Do design verification and/or validation activities produce any unexpected issues of safety or effectiveness?
Session #: 6
Duration: 30 minutes
Learning Objectives: Considerations for risk-based assessments of modified devices: This session provides guidance on the principal factors to consider in conducting a risk-based assessment to determine whether a device change leads to a significant change in the device’s risk profile.
1. Likelihood or probability of occurrence of harm
2. Severity of harm
3. Device effectiveness
Who will Benefit
• Quality Managers
• Quality Engineers
• Regulatory Affairs
• Small business owners
• GxP
• Consultants
• Quality VPs
• IT VPs
• Lab Directors
• Scientists
• FDA investigators
• Other regulatory agency investigators
Industries who can attend
Learning Objectives:
1. The main types of changes that might be made to a device
2. Labeling changes
3. Technology, engineering, and performance changes
4. Materials changes
5. Technology, engineering, performance, and materials changes for in vitro diagnostic devices (IVDs)
6. Considerations for risk-based assessments of modified devices
Angela Bazigos.CEO of Touchstone Technologies Inc. She has 40 years of experience in the Life Sciences & Healthcare Industries. Experience combines Quality Assurance, Regulatory Compliance, Business Administration, Information Technology, Project Management, Clinical Lab Science, Microbiology, Food Safety, Turnarounds and Business Development. Past employers / clients include Roche, Novartis, Genentech & PriceWaterhouseCoopers. Positions include Chief Compliance Officer at Morf Media. Co-authored & prototyped 21 CFR 11 guidance with FDA. Co-authored Computerized Systems in Clinical Research w/ FDA. Patent on speeding up software compliance. Recently quoted in Wall Street Journal for using training to bring regulatory compliance to the Boardroom. National Trainer for Society of Quality Assurance. Comments / collaborates with FDA on new guidance documents. Former President of Pacific Regional Chapter of Society of Quality Assurance. Stanford’s Who’s Who for Life Sciences.
$295 One Dial-in One Attendee|$395 One Dial In - Max 10 attendees |$995 Multiple locations upto 5 dial in|$345 Available within 24 hrs after |$489 CD/DVD will be dispatched after |
https://worldcomplianceseminars.com/webinardetails/319 |
conference manager
Phone: 08442677299
Email: subscribe (at) worldcomplianceseminars.com |
|
|
| Report Abuse |
|
|
| |
| |
|
| List your Event |
| | Similar Events | FL: 3-hrs Virtual Training 2018 Latest FDA thinking on deciding when
3-hrs Virtual Training 2018 Latest FDA thinking on deciding when to Submit a 510(k) for a Change to an Existing Device – FDA’s Final Guidance
Description
A premarket notification (510(k)) is required when a legally marketed device subject
Date Posted: 31-May-18
| FL: 3-hrs Webinar-Deciding When to Submit a 510(k) for a Change to an Exis
3-hrs Webinar-Deciding When to Submit a 510(k) for a Change to an Existing Device – FDA’s Final Guidance
Description
A premarket notification (510(k)) is required when a legally marketed device subject to 510(k) requirements is about to be
Date Posted: 30-Apr-18
| Houston: Implementing a Change Control Quality System Successfully
DESCRIPTION
This course will help attendees understand the fundamental change control steps and processes. It will focus on change proposals, assessments, execution and final implementation. The importance of proper planning, critical thinking s
Date Posted: 15-Apr-16
| FL: Live Webinar Understanding and Applying the New EU Medical Device Regu
Live Webinar Understanding and Applying the New EU Medical Device Regulations (EMDR)
Description
The European Parliament just adopted the Medical Devices (MDR) and In vitro Diagnostic Medical Devices (IVDR) regulations. The adoption
Date Posted: 26-Apr-18
| FL: Live Webinar FDA’s Final Rule Regarding Device Establishment Registrat
Live Webinar FDA’s Final Rule Regarding Device Establishment Registration and Listing: Procedure on How to Register and List
Description
Device firms, establishments or facilities that are involved in the production and distribution of me
Date Posted: 27-Apr-18
| FL: Live Webinar FDA’s Final Rule Regarding Device Establishment Registrat
Live Webinar FDA’s Final Rule Regarding Device Establishment Registration and Listing: Procedure on How to Register and List
Description
Device firms, establishments or facilities that are involved in the production and distribution of medica
Date Posted: 08-May-18
| FL: Live Webinar New and Expected Guidances on Data Standards and Electron
Live Webinar New and Expected Guidances on Data Standards and Electronic Submissions for Drugs and Medical Products
Description
Each FDA center has different guidelines and processes to follow in order to have a successful submission for the re
Date Posted: 30-Apr-18
| FL: Live Webinar New and Expected Guidances on Data Standards and Electron
Live Webinar New and Expected Guidances on Data Standards and Electronic Submissions for Drugs and Medical Products
Description
Each FDA center has different guidelines and processes to follow in order to have a successful submission for the re
Date Posted: 11-May-18
| FL: 2018 Update: How to Write Effective SOPs for FDA inspection
2018 Update: How to Write Effective SOPs for FDA inspection & Regulatory Compliance
Description
Standard Operating Procedures (SOPs) are required by law for companies that are regulated by the Code of Federal Regulations such as
Date Posted: 27-Apr-18
| FL: Live Webinar Use / Human Factors Engineering to Satisfy the New IEC 62
Live Webinar Use / Human Factors Engineering to Satisfy the New IEC 62366-1, -2
Description
IEC has released a new medical device usability standard, IEC 62366-1:2015 -- Part 1: “Application of the new Usability Engineering Standard to Medic
Date Posted: 30-Apr-18
| FL: Live Webinar Construct and Manage the Technical File and Design Dossie
Live Webinar Construct and Manage the Technical File and Design Dossier
Description
This Webinar will provide a substantive overview and outline differences between the Technical File and Design Dossier for those device firms dealing with the glo
Date Posted: 30-Apr-18
| FL: Live Webinar Design Control Under 21 CFR 820 (the CGMPs) and ISO 13485
Live Webinar Design Control Under 21 CFR 820 (the CGMPs) and ISO 13485
Description
The FDA CGMPs (21 CFR 820.30) and ISO QMS’ (ISO 13485:2016 7.3) expect companies to perform meaningful, results driven Design Control act
Date Posted: 27-Apr-18
| DC / U.S. Capitol : 2 Days Workshop: FDA 21 CFR Part 11 Compliance – Validation Seminar
2 Days Workshop: FDA 21 CFR Part 11 Compliance – Validation Seminar 2018
Location 1: Washington DC
Jun 28 - 29
Description
GxP records generated by spreadsheet calculations are electronic records and should comply with FDA’s 21 CF
Date Posted: 21-May-18
| DC / U.S. Capitol : 2 Days Workshop: FDA 21 CFR Part 11 Compliance – Validation Seminar
2 Days Workshop: FDA 21 CFR Part 11 Compliance – Validation Seminar 2018
Description
Spreadsheets such as Excel, are available for creating a wide range of end user applications, including widespread use in the laboratory, creating customiz
Date Posted: 17-May-18
| DC / U.S. Capitol : 2 Days Workshop: FDA 21 CFR Part 11 Compliance – Validation Seminar
2 Days Workshop: FDA 21 CFR Part 11 Compliance – Validation Seminar 2018
Location 1: Washington DC
Jun 28 - 29
Description
Spreadsheets such as Excel, are available for creating a wide range of end user applications, including wides
Date Posted: 04-May-18
|
|
Map locations are shown as per geocoding services and they depeneds on the accuracy of the address. If address is wrong it may show wrong map. If you put a listing which shows wrong map, please remove the listing and create a new one with correct address details.
Please note: The information on this site is submitted by users. CanadianDesi never checks accuracy of the information. Please use this information at your risk. If you have any question or concern regarding this listing, or you know that the above information is not accurate, please Contact Us. Thanks.
|
| Please note: The information on this site is submitted by users. CanadianDesi never checks accuracy of the information. Please use this information at your risk. If you have any question or concern regarding this listing, or you know that the above information is not accurate, please Contact Us. Thanks.
|
|
